ERBB2 and breast carcinoma: In this study, we demonstrate that a HER2 inhibitor insufficiently suppresses p4EBP1 as well as pS6 in PIK3CA-mutant HER2+ breast cancer cell lines (Fig. 3a), and that these cells are resistant to the HER2 inhibitor.